ArticleFrontiers in oncology2026
A cancer-predisposing syndrome is always there: a sequential occurrence of acute lymphoblastic leukemia after acute myeloid leukemia in a child with down syndrome.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Down syndrome (DS) is the most common cancer predisposing syndrome (CPS) associated with a markedly increased risk of pediatric hematologic malignancies, specifically acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Although both AML and ALL occur more frequently in children with DS than in the general pediatric population, the sequential development of both malignancies in the same patient is extremely rare. Results: Here we report the case of a child with DS who initially developed an AML and subsequentially an ALL, while the myeloid leukemia was in remission. Discussion: This case underscores the rarity of sequential AML and ALL in DS patients and supports the hypothesis that these leukemias represent biologically distinct diseases. Trisomy 21 has a central role in predisposing to both myeloid and lymphoid leukemogenesis through profound alterations of hematopoiesis and gene deregulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.